Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q01082
UPID:
SPTB2_HUMAN
Alternative names:
Beta-II spectrin; Fodrin beta chain; Spectrin, non-erythroid beta chain 1
Alternative UPACC:
Q01082; B2RP63; O60837; Q16057; Q53R99; Q59ER3; Q8IX99
Background:
Spectrin beta chain, non-erythrocytic 1, also known as Beta-II spectrin, plays a pivotal role in the calcium-dependent movement of the cytoskeleton at the membrane. Its interaction with calmodulin and involvement in secretion underscore its critical function in central nervous system development and function.
Therapeutic significance:
Linked to developmental delay, impaired speech, and behavioral abnormalities, understanding the role of Spectrin beta chain, non-erythrocytic 1 could unveil new therapeutic strategies for addressing these complex disorders.